CDK2 and bladder transitional cell carcinoma: Most recently, Kuo et al revealed that PR‐619 treatment induced G0/G1 cell cycle arrest in bladder urothelial carcinoma cells with decreased p‐Histone H3 (Ser10) and increased p21 and phospho‐CDK2 (Tyr15).34